The role of local ablative therapy in patients with advanced invasive mucinous adenocarcinoma of the lung.
Adenocarcinoma
Local ablative therapy
Lung neoplasms
Mucinous
Prognosis
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
04 Sep 2024
04 Sep 2024
Historique:
received:
15
07
2024
accepted:
22
08
2024
medline:
4
9
2024
pubmed:
4
9
2024
entrez:
4
9
2024
Statut:
epublish
Résumé
Invasive mucinous adenocarcinoma (IMA) of the lungs is a rare subtype of lung adenocarcinoma with a limited understanding of its prognosis, particularly in advanced stages. This study aimed to assess the prognosis of patients with advanced IMA by focusing on treatment modalities. This single-center retrospective study evaluated 33 patients with IMAs diagnosed with advanced-stage disease or disease progression after curative treatment between 2011 and 2021. The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS). OS and PFS were calculated from the date of the diagnosis of advanced IMA. The study cohort included 13 patients at the initial advanced stage and 20 patients who progressed after curative treatment. Treatment modalities included conventional chemotherapy in 24 patients (72.7%), targeted therapy in seven (21.2%), immunotherapy in 13 (39.4%), and local ablative therapy (LAT) in 13 (39.4%). The median OS was 32 months (95% confidence interval [CI], 2.9-61.0), with LAT significantly associated with improved OS compared to non-LAT treatment (not reached vs. 11.3 months, p = 0.001). However, there was no significant difference in OS based on conventional chemotherapy (p = 0.396), targeted therapy (p = 0.655), or immunotherapy (p = 0.992). In multivariate analysis, LAT remained an independent prognostic factor for OS (hazard ratio, 0.125; 95% CI, 0.026-0.608; p = 0.01). PFS was 8.6 months (95% CI, 3.6-13.7), with no significant differences observed among the treatment modalities. Our findings suggest that LAT may provide favorable survival outcomes in patients with advanced IMA.
Identifiants
pubmed: 39230677
doi: 10.1007/s00432-024-05931-y
pii: 10.1007/s00432-024-05931-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
409Informations de copyright
© 2024. The Author(s).
Références
Boland JM, Maleszewski JJ, Wampfler JA, Voss JS, Kipp BR, Yang P, Yi ES (2018) Pulmonary invasive mucinous adenocarcinoma and mixed invasive mucinous/nonmucinous adenocarcinoma-a clinicopathological and molecular genetic study with survival analysis. Hum Pathol 71:8–19. https://doi.org/10.1016/j.humpath.2017.08.002
doi: 10.1016/j.humpath.2017.08.002
pubmed: 28823574
Cha YJ, Shim HS (2017) Biology of invasive mucinous adenocarcinoma of the lung. Transl Lung Cancer Res 6:508–512. https://doi.org/10.21037/tlcr.2017.06.10
doi: 10.21037/tlcr.2017.06.10
pubmed: 29114467
pmcid: 5653530
Cha YJ, Kim HR, Lee HJ, Cho BC, Shim HS (2016) Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. Lung Cancer 102:82–88. https://doi.org/10.1016/j.lungcan.2016.11.004
doi: 10.1016/j.lungcan.2016.11.004
pubmed: 27987593
Dilly AK, Honick BD, Frederick R, Elapavaluru A, Velankar S, Makala H et al (2021) Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer. Transl Res 229:100–114. https://doi.org/10.1016/j.trsl.2020.10.005
doi: 10.1016/j.trsl.2020.10.005
pubmed: 33164812
Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M et al (2023) Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non-small-cell Lung Cancer: 5-Year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol 41:1992–1998. https://doi.org/10.1200/jco.22.01989
doi: 10.1200/jco.22.01989
pubmed: 36809080
pmcid: 10082311
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE et al (2016) The IASLC Lung Cancer Staging Project: proposals for revision of the TNM Stage groupings in the Forthcoming (Eighth) Edition of the TNM classification for Lung Cancer. J Thorac Oncol 11:39–51. https://doi.org/10.1016/j.jtho.2015.09.009
doi: 10.1016/j.jtho.2015.09.009
pubmed: 26762738
Gow CH, Hsieh MS, Liu YN, Lee YH, Shih JY (2021) Clinicopathological features and survival outcomes of primary pulmonary invasive mucinous adenocarcinoma. Cancers (Basel) 13. https://doi.org/10.3390/cancers13164103
Guo M, Tomoshige K, Meister M, Muley T, Fukazawa T, Tsuchiya T et al (2017) Gene signature driving invasive mucinous adenocarcinoma of the lung. EMBO Mol Med 9:462–481. https://doi.org/10.15252/emmm.201606711
doi: 10.15252/emmm.201606711
pubmed: 28255028
pmcid: 5376761
Hata A, Katakami N, Fujita S, Kaji R, Imai Y, Takahashi Y, Nishimura T, Tomii K, Ishihara K (2010) Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma. J Thorac Oncol 5:1197–1200. https://doi.org/10.1097/JTO.0b013e3181e2a2bc
doi: 10.1097/JTO.0b013e3181e2a2bc
pubmed: 20661086
Hishida T, Yoshida J, Aokage K, Nagai K, Tsuboi M (2016) Postoperative oligo-recurrence of non-small-cell lung cancer: clinical features and survival†. Eur J Cardiothorac Surg 49:847–853. https://doi.org/10.1093/ejcts/ezv249
doi: 10.1093/ejcts/ezv249
pubmed: 26201958
Ichinokawa H, Ishii G, Nagai K, Kawase A, Yoshida J, Nishimura M et al (2013) Distinct clinicopathologic characteristics of lung mucinous adenocarcinoma with KRAS mutation. Hum Pathol 44:2636–2642. https://doi.org/10.1016/j.humpath.2013.05.026
doi: 10.1016/j.humpath.2013.05.026
pubmed: 24119562
Jang YJ, Hyun DG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, Ji W, Lee JC (2021) Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung. BMC Cancer 21:731. https://doi.org/10.1186/s12885-021-08472-6
doi: 10.1186/s12885-021-08472-6
pubmed: 34174841
pmcid: 8235206
Lakshmanan I, Ponnusamy MP, Macha MA, Haridas D, Majhi PD, Kaur S, Jain M, Batra SK, Ganti AK (2015) Mucins in lung cancer: diagnostic, prognostic, and therapeutic implications. J Thorac Oncol 10:19–27. https://doi.org/10.1097/jto.0000000000000404
doi: 10.1097/jto.0000000000000404
pubmed: 25319180
Lee HY, Cha MJ, Lee KS, Lee HY, Kwon OJ, Choi JY et al (2016) Prognosis in Resected Invasive Mucinous adenocarcinomas of the lung: related factors and comparison with Resected Nonmucinous Adenocarcinomas. J Thorac Oncol 11:1064–1073. https://doi.org/10.1016/j.jtho.2016.03.011
doi: 10.1016/j.jtho.2016.03.011
pubmed: 27016260
Na KJ, Kim YT (2023) The new oligometastatic disease state and associated therapies in non-small cell lung cancer: a narrative review. J Surg Oncol 127:282–287. https://doi.org/10.1002/jso.27165
doi: 10.1002/jso.27165
pubmed: 36464990
Ni Y, Ye X, Yang X, Huang G, Li W, Wang J et al (2020) Microwave ablation for non-small cell lung cancer with synchronous solitary extracranial metastasis. J Cancer Res Clin Oncol 146:1361–1367. https://doi.org/10.1007/s00432-020-03176-z
doi: 10.1007/s00432-020-03176-z
pubmed: 32146563
Parikh RB, Cronin AM, Kozono DE, Oxnard GR, Mak RH, Jackman DM et al (2014) Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. Int J Radiat Oncol Biol Phys 89:880–887. https://doi.org/10.1016/j.ijrobp.2014.04.007
doi: 10.1016/j.ijrobp.2014.04.007
pubmed: 24867533
Peng L, Guo J, Kong L, Huang Y, Tang N, Zhang J et al (2022) Efficacy of immunotherapy in KRAS-mutant advanced NSCLC: a real-world study in a Chinese population. Front Oncol 12:1070761. https://doi.org/10.3389/fonc.2022.1070761
doi: 10.3389/fonc.2022.1070761
pubmed: 36741723
Rim CH, Cho WK, Park S, Yoon WS, Yang DS (2023) Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis. Int J Surg 109:1006–1014. https://doi.org/10.1097/js9.0000000000000339
doi: 10.1097/js9.0000000000000339
pubmed: 36974686
pmcid: 10389458
Rosas D, Raez LE, Russo A, Rolfo C (2021) Neuregulin 1 Gene (NRG1). A potentially new Targetable Alteration for the treatment of Lung Cancer. Cancers (Basel) 13. https://doi.org/10.3390/cancers13205038
Saito T, Tsuta K, Honda O, Ishida M, Yamaka R, Tanaka N et al (2020) Prognostic impact of mucin spread, tumor cell spread, and invasive size in invasive mucinous adenocarcinoma of the lung. Lung Cancer 146:50–57. https://doi.org/10.1016/j.lungcan.2020.05.030
doi: 10.1016/j.lungcan.2020.05.030
pubmed: 32512273
Schanne DH, Heitmann J, Guckenberger M, Andratschke NHJ (2019) Evolution of treatment strategies for oligometastatic NSCLC patients - a systematic review of the literature. Cancer Treat Rev 80:101892. https://doi.org/10.1016/j.ctrv.2019.101892
doi: 10.1016/j.ctrv.2019.101892
pubmed: 31522079
Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q et al (2015) Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the lung. J Thorac Oncol 10:1156–1162. https://doi.org/10.1097/jto.0000000000000579
doi: 10.1097/jto.0000000000000579
pubmed: 26200269
Sun XW, Ding YJ, Zhang YY, Chen PL, Yan YR, Shen JM, Li QY (2018) Favorable response to pemetrexed, cisplatin and bevacizumab in invasive mucinous adenocarcinoma: a case report and literature review. Mol Clin Oncol 9:192–196. https://doi.org/10.3892/mco.2018.1651
doi: 10.3892/mco.2018.1651
pubmed: 30101020
pmcid: 6083419
Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y et al (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285. https://doi.org/10.1097/JTO.0b013e318206a221
doi: 10.1097/JTO.0b013e318206a221
pubmed: 21252716
pmcid: 4513953
Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB et al (2015) The 2015 World Health Organization Classification of Lung Tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10:1243–1260. https://doi.org/10.1097/jto.0000000000000630
doi: 10.1097/jto.0000000000000630
pubmed: 26291008
Wang T, Yang Y, Liu X, Deng J, Wu J, Hou L et al (2021) Primary invasive mucinous adenocarcinoma of the lung: prognostic value of CT imaging features combined with clinical factors. Korean J Radiol 22:652–662. https://doi.org/10.3348/kjr.2020.0454
doi: 10.3348/kjr.2020.0454
pubmed: 33236544
Xu X, Li N, Wang D, Chen W, Fan Y (2021) Clinical relevance of PD-L1 expression and CD8 + T cells’ infiltration in patients with lung invasive mucinous adenocarcinoma. Front Oncol 11:683432. https://doi.org/10.3389/fonc.2021.683432
doi: 10.3389/fonc.2021.683432
pubmed: 34249733
pmcid: 8264667
Xu M, Hao Y, Zhou H, Shi Z, Si J, Song Z (2023) Comparison of the immunotherapy efficacy between invasive mucinous and non-mucinous adenocarcinoma in advanced lung cancer patients with KRAS mutation: a retrospective study. Med Oncol 40:198. https://doi.org/10.1007/s12032-023-02059-w
doi: 10.1007/s12032-023-02059-w
pubmed: 37294384
Zeissig MN, Ashwood LM, Kondrashova O, Sutherland KD (2023) Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer 9:955–967. https://doi.org/10.1016/j.trecan.2023.07.010
doi: 10.1016/j.trecan.2023.07.010
pubmed: 37591766
Zhang C, Ma N, Zhang Q, Zheng K, Sun C, Tang X, Li X, Zhao J (2021) Evaluation of local aggressive lung therapy versus systemic therapy in oligometastatic non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis 13:5899–5910. https://doi.org/10.21037/jtd-21-957
doi: 10.21037/jtd-21-957
pubmed: 34795938
pmcid: 8575811